After racing out to a fast start in its first year on the market, Novo Nordisk’s GLP-1 diabetes superstar Ozempic is already proving a darling for the Danish drugmaker. Now, a heart-helping FDA approval will likely spell even more success
read moreBayer is among drugmakers marketing new “tumor-agnostic” medicines that target specific types of tumors, regardless of their location in the body. But the company’s new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where
read moreSun Piaoyang, who’s led Jiangsu Hengrui Medicine for 30 years and forms half of China’s fourth-wealthiest family, is stepping down as the domestic pharma major’s chairman. Though he still retains control of the company, the transition comes at a critical
read moreThe recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months. More: Ibrance given NICE green light in breast cancer Source: News
read moreThe plans were “ambitions”, and primary care is not being given the time, support and funding it needs. More: Government health commitments just a ‘pipedream’ Source: News
read moreThe organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs. More: Vitrakvi deemed ‘not cost-effective’ by NICE Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals